Pro-and anti-inflammatory cytokines in Steatosis and steatohepatitis

Obesity Surgery

Volumn 20, Issue 7, 2010, Pages 906-912

  Rabelo, Fabiola ^a   Oliveira, Claudia P M S ^a   Faintuch, Joel ^a   Mazo, Daniel F C ^a   Lima, Vicencia M R ^a   Stefano, Jose Tadeu ^a   Barbeiro, Hermes V ^a   Soriano, Francisco G ^a   Ferreira Alves, Venancio A ^a   Carrilho, Flair J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti inflammatory cytokines; Diabetes; IL 10; IL 6; Inflammation; NASH; Obesity; Steatohepatitis; Steatosis; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; STEATOSIS;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77955655242     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-010-0181-4     Document Type: Article

References (29)

1. Mummadi RR, Kasturi KS, Chennareddyqari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396-1402
2. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532-540
3. Dogru T, Ercin CN, Erdem G, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:3217-3218
4. Wieckowska A, Papouchado B, ZhenZheng L, et al. Increased hepatic and circulating interleukin 6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372-1379
5. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430-1437
6. Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology. 2005;52:1549-1553
7. Gruady SM, Hansen B, Smith Jr SC, et al. Clinical management of metabolic syndrome: report of the American Heart Association/ National Heart, Lung and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-556
8. Kleiner DE, Brunt EM, Natta MV, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321
9. Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006;26:39-45.
10. Naveau S, Balian A, Capron F, et al. Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. Gastroenterol Clin Biol. 2005;29:269-274
11. Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and atherosclerosis. Am J Gastroenterol. 2008;103:1959-1965
12. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412-421
13. Isaacs A. Interferon as a factor of recovery from vírus infection. Proc R Soc Med. 1962;55:725-726
14. Salgado W, Cunha FQ, Santos JS, et al. Early identification of infectious complications in bariatric surgery by the determination of peritoneal and systemic cytokines. Obes Surg. 2009;19:867-872
15. Tarantino G, Marra M, Contaldo F, et al. Basal metabolic rate in morbidly obese patients with nonalcoholic fatty liver disease. Clin Invest Med. 2008;31(1):E24-9.
16. Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1946-1952
17. Lee YM, Sutedja DS, Wai CT, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int. 2008;2:196-201.
18. Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring). 2009;17:1696-1701
19. Rosenson RS. Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. Cardiovasc Drugs Ther. 2009;23:289-294
20. Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity Crecative protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of severity of fibrosis in NASH. J Gastroenterol. 2007;42:573-582
21. Peng XD, Dai LL, Huang CQ, et al. Relationship between antifibrotic effect of Panax notoginseng saponins and serum cytokines in rat hepatic fibrosis. Biochem Biophys Res Commun. 2009;388:31-34
22. de Lalla C, Galli G, Aldrighetti L. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol. 2004;173:1417-1425
23. Hong EG, Ko HJ, Cho YR, et al. Interleukin-10 prevents dietinduced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. 2009;58:2525-2535
24. Elinav E, Pappo O, Sklair-Levy M, et al. Amelioration of nonalcogholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J Pathol. 2006;208:74-81.
25. Estep JM, Baranova A, Hossain N, et al. Expression of cytokine signaling genes in morbidly obese patients with nonalcoholic steatohepatitis and hepatic fibrosis. Obes Surg. 2009;19:617-624
26. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366-1374
27. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
28. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197-208.
29. Chagas AL, Kikuchi LO, Oliveira CP, et al. Does hepatocellular carcinoma in nonalcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res. 2009;42:958-962